Michael Nelson, JD

Chief Executive Officer and Co-Founder, Intrommune Therapeutics

Michael Nelson has served as Chief Executive Officer of Intrommune since its founding in 2013. Mr. Nelson has been the Founder or Co-Founder and Chief Executive Officer or Chief Financial Officer of several early stage healthcare companies. Mr. Nelson recently stepped down as the Chief Financial Officer of Immunovent, LLC, a company developing a novel allergy diagnostic and Allovate, LLC, from which Intrommune is licensing its food allergy oral mucosal immunotherapy platform.

Mr. Nelson is a periodic advisor to Westwood Capital, LLC with over 20 years of investment banking, legal, management, and investing experience. Mr. Nelson was an Associate Director at Barclays Capital, where he helped manage a $2 billion proprietary portfolio focused on special situations, including risk arbitrage, and the healthcare sector. Mr. Nelson was also Vice President at ING Capital LLC, where he helped manage a $400 million portfolio. Mr. Nelson was an investment banker in the health care investment banking group at CIBC World Markets, where he specialized in health care services and information and pharmaceutical technology for private and public offerings and M&A.

Mr. Nelson began his career as an attorney with the law firm of Willkie Farr & Gallagher in the Bankruptcy & Business Reorganization department specializing in debtor and creditor representation and structured finance counseling in the securitization and structured finance area. Mr. Nelson also practiced law as a senior associate with Dewey Ballantine. Mr. Nelson received a B.S. in Biology from Cornell University and a J.D. from New York University School of Law.

http://www.intrommune.com/